Skip to content
TrialScanner

NCT03543813

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Phase 1/Phase 2CompletedCTMXLead

Registry record

Lead sponsor
CytomX Therapeutics
Conditions
Solid Tumor, Adult; Head and Neck Cancer; Non Small Cell Lung Cancer; Diffuse Large B Cell Lymphoma; Esophageal Cancer
Primary completion
Jun 1, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03543813 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03543813: PROCLAIM-CX-2029: A Trial to... | TrialScanner